A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: DRUG: enfortumab vedotin|DRUG: pembrolizumab
Sponsor: Astellas Pharma Global Development, Inc.
Collaborators: Seagen Inc.|Merck Sharp & Dohme LLC